Yantai Dongcheng Pharmaceutical Group (SHE:002675) received marketing approval from China's drug administrator for its fluorine [18F] sodium fluoride injection.
This PET imaging agent is used to detect bone metastases in breast, prostate and lung cancers, according to a Wednesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company rose 1% in recent trade.